Startup entity

DuplexSeq

Technology

acquisition is the sole category represented across all 1 tracked stories. Impilo is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 4.5 for the broader beat in this window.

Last mentioned: Feb 26, 2026

Entity pulse

Recent coverage · DuplexSeq

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about DuplexSeq

acquisition is the sole category represented across all 1 tracked stories. Impilo is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 4.5 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 6.9 in the same window. DuplexSeq appears in 1 tracked Startup story from February 26, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 42 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering DuplexSeq. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning DuplexSeq 1

Acquisitions Neutral

Scantox Bolsters Genetic Toxicology Portfolio with TwinStrand Acquisition

Scantox has acquired the DuplexSeq™ nonclinical genomics safety business from TwinStrand Biosciences, integrating ultra-sensitive DNA sequencing technology into its preclinical CRO services. The move positions Scantox as a leader in high-precision genetic toxicology, offering pharmaceutical clients 10,000x greater sensitivity in identifying mutagenic risks.

2 sources

DuplexSeq is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.